Amyloidosis: Causes, Symptoms, Complications, Diagnosis and Treatment

What is Amyloidosis?

Amyloidosis is a rare and complex group of diseases that occur when certain proteins, which normally circulate in the bloodstream in their correct, functional three-dimensional structure, begin to fold abnormally. Instead of maintaining their native configuration, these proteins misfold and aggregate with one another, forming insoluble fibrous deposits called amyloid fibrils. These deposits accumulate progressively in the tissues and organs of the body, physically impregnating them and progressively impairing their normal function.

A useful analogy: imagine that the structural proteins of a building’s framework begin to warp and interlock in the wrong configuration, creating dense, insoluble tangles that clog the walls and floor of the building, making it increasingly rigid, dysfunctional, and ultimately unable to perform its intended purpose. This is essentially what amyloid deposits do to the organs they infiltrate.

Over 40 distinct proteins have been identified as capable of forming amyloid deposits in humans, leading to more than 40 recognized forms of amyloidosis, each with its own causative protein, characteristic organ tropism, clinical presentation, and therapeutic approach. Despite this diversity, all forms share the hallmark pathological finding: the accumulation of misfolded protein fibrils in a beta-pleated sheet configuration that is resistant to normal cellular degradation and proteolysis.

Amyloidosis can be:

• Systemic: affecting multiple organs throughout the body simultaneously
• Localized: confined to a single organ or tissue

The disease can manifest at any age, though most forms predominantly affect middle-aged and older adults. Currently, there is no definitive cure for most forms of amyloidosis, though the therapeutic landscape has been transformed in recent years by the development of targeted, disease-modifying treatments that can significantly slow or halt disease progression.

Transthyretin Amyloidosis (ATTR)

A particularly important and increasingly recognized form of amyloidosis is transthyretin amyloidosis (ATTR), caused by the deposition of misfolded transthyretin (TTR) protein, a protein produced by the liver that normally serves as a transport vehicle for thyroid hormones and vitamin A in the bloodstream.

The biological mechanism of ATTR:

Transthyretin normally exists as a tetramer, a stable structure composed of four identical protein subunits (monomers) held together by non-covalent interactions. This tetrameric structure is essential for the protein’s function and stability. In ATTR amyloidosis, the tetramer becomes thermodynamically unstable and dissociates into individual monomers. These freed monomers are prone to misfolding and aggregation into amyloid fibrils, like “building blocks” that detach from their orderly structure and reassemble in a disorganized, pathological configuration. The resulting fibrils deposit predominantly in the heart, peripheral nerves, and various other tissues.

ATTR amyloidosis exists in two principal forms:

1. Wild-type ATTR amyloidosis (ATTRwt) - “Senile” cardiac amyloidosis: This form occurs in the absence of any genetic mutation; the protein produced is structurally normal, but undergoes age-related destabilization and misfolding as part of the natural aging process. It almost exclusively affects older men (predominantly over the age of 65, with increasing prevalence with advancing age), though women can also be affected. The primary target organ is the heart, with amyloid fibrils depositing in the myocardium (heart muscle), producing progressive cardiac stiffness and dysfunction.

Clinical manifestations in affected patients include:

• Cardiac arrhythmias: including atrial fibrillation (very common), heart block, and other conduction abnormalities
• Cardiomegaly: pathological enlargement of the heart due to progressive amyloid infiltration and compensatory hypertrophy
• Orthostatic hypotension: a drop in blood pressure upon standing, caused by autonomic dysfunction
• Progressive heart failure: as the myocardium becomes increasingly rigid and unable to relax and fill effectively (diastolic dysfunction), and ultimately unable to pump adequate cardiac output (systolic dysfunction)
• Carpal tunnel syndrome: amyloid deposits in the carpal tunnel ligament, often presenting years before cardiac symptoms, are increasingly recognized as an early warning sign of underlying ATTRwt

Because this form is linked to the natural aging of the protein (rather than a genetic mutation), it is termed “wild-type” or “senile”. It is significantly more common than previously recognized: autopsy studies suggest that amyloid deposits can be found in the hearts of a substantial proportion of individuals over 80 years of age. Many cases are still misdiagnosed as hypertensive heart disease or “diastolic dysfunction of unknown cause”.

2. Hereditary ATTR amyloidosis (ATTRv - variant): In this form, a genetic mutation in the TTR gene produces an abnormal transthyretin protein that is inherently less stable than the wild-type protein and therefore misfolds and aggregates more readily. Over 120 different TTR mutations have been identified, each associated with a specific clinical phenotype varying in age of onset, severity, and primary organ involvement. Hereditary ATTR amyloidosis is transmitted in an autosomal dominant pattern, meaning a single mutated copy of the TTR gene is sufficient to cause disease. Common variants include Val30Met (prevalent in Portugal, Sweden, and Japan, causing primarily polyneuropathy), Val122Ile (predominantly affecting individuals of West African descent, causing primarily cardiomyopathy), and Ile68Leu (among others).

---

Causes

The fundamental pathophysiological event common to all forms of amyloidosis is the misfolding of specific proteins into beta-sheet-rich conformations that aggregate into insoluble fibrillar deposits. However, the specific molecular triggers and mechanisms differ substantially across the different types.

General mechanisms contributing to amyloid fibril formation and deposition include:

• Pathological protein degradation (proteolysis): abnormal cleavage of protein precursors (such as serum amyloid A protein or immunoglobulin light chains) generates fragments that are more prone to misfolding and aggregation
• Deficient or absent proteolysis: failure of normal cellular protein quality control mechanisms (the ubiquitin-proteasome system and autophagy-lysosomal pathway) to degrade aberrant proteins allows them to accumulate
• Genetic mutations: mutations in the genes encoding amyloidogenic proteins alter their thermodynamic stability or transport properties, making them more likely to misfold and aggregate, even at normal tissue concentrations
• Chronic overproduction: sustained overproduction of amyloidogenic proteins (such as immunoglobulin light chains in plasma cell dyscrasias) overwhelms the body’s capacity for normal protein clearance
• Chronic infections and inflammation: sustained inflammatory states drive the overproduction of acute-phase proteins (such as serum amyloid A) whose persistent elevation promotes amyloid A fibril formation
• Additional incompletely understood mechanisms: including altered protein-chaperone interactions, disrupted glycosaminoglycan binding, oxidative modifications, and changes in the local microenvironment of specific tissues

In localized forms of amyloidosis, the depositing protein is typically produced locally at the site of deposition rather than being deposited from systemic circulation. For example, in Alzheimer’s disease, amyloid-beta peptide is generated locally by neurons; in medullary thyroid carcinoma, calcitonin is locally overproduced by malignant C cells and forms local amyloid deposits.

In approximately 90% of systemic amyloidosis cases, the deposits are composed of structurally altered amyloid protein fibrils. In the remaining 10%, they consist of other molecules including keratin, calcitonin, and atrial natriuretic factor.

Classification of Amyloidosis Types

The international nomenclature of amyloidosis classifies each type using the prefix “A” (for amyloid) followed by a letter or abbreviation designating the specific fibril protein. The most clinically important forms are:

AL Amyloidosis (Amyloid Light Chain - Primary Amyloidosis)

AL amyloidosis is the most common form of systemic amyloidosis in high-income countries, accounting for approximately 70% of cases. It is caused by the deposition of immunoglobulin light chains (specifically, fragments of the variable region of kappa or lambda light chains) produced by a clonal plasma cell population in the bone marrow.

In AL amyloidosis, the bone marrow produces an abnormal clone of plasma cells that generate structurally aberrant light chain proteins. These misfolded light chain proteins are secreted into the circulation and deposit throughout the body, primarily in the kidneys, heart, liver, peripheral and autonomic nervous system, and gastrointestinal tract.

AL amyloidosis is closely associated with multiple myeloma (a malignant proliferative disorder of plasma cells), though not all AL amyloidosis patients have overt myeloma. Many have a lower-grade condition called monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma.

AA Amyloidosis (Amyloid A protein - Reactive or Secondary Amyloidosis)

AA amyloidosis, previously termed “secondary amyloidosis”, occurs as a complication of chronic, sustained inflammatory states. The amyloidogenic protein is serum amyloid A (SAA), an acute-phase reactant produced by the liver in large quantities during any significant inflammatory stimulus. In most individuals with transient inflammation, SAA levels rise and then normalize without causing harm. However, in patients with persistent chronic inflammation, chronically elevated SAA levels eventually lead to the deposition of AA amyloid fibrils, primarily in the kidneys, but also in the liver, spleen, and gastrointestinal tract.

Common underlying conditions associated with AA amyloidosis include:

• Rheumatoid arthritis, historically the most common cause in Western countries
• Crohn’s disease and ulcerative colitis
• Familial Mediterranean fever (FMF) and other periodic fever syndromes
• Chronic osteomyelitis, bronchiectasis, and other chronic infections
• Inflammatory bowel disease
• Ankylosing spondylitis and other seronegative spondyloarthropathies

Dialysis-Related Amyloidosis (DRA - Beta-2 Microglobulin Amyloidosis)

DRA is caused by the deposition of beta-2 microglobulin (β2M), a protein component of MHC class I molecules, which accumulates in the blood of patients with severe chronic kidney disease because it cannot be adequately filtered by standard dialysis membranes. After several years of dialysis treatment, the persistently elevated circulating β2M leads to amyloid deposition, predominantly in bones, joints, and tendons (particularly the carpal tunnel and the spine, causing destructive spondyloarthropathy).

DRA is the most common form of amyloidosis in patients who have been on renal dialysis for more than 5 years, though its prevalence is declining in patients treated with newer, more permeable high-flux dialysis membranes.

Hereditary/Familial Amyloidoses (ATTR, AApoAI, and others)

These are rare, autosomal dominant conditions caused by mutations in genes encoding amyloidogenic proteins. The most important include:

• ATTRv (Hereditary Transthyretin Amyloidosis): caused by mutations in the TTR gene, as described above. It primarily affects peripheral nerves (familial amyloid polyneuropathy - FAP) and/or the heart (familial amyloid cardiomyopathy - FAC), depending on the specific mutation.
• AApoAI (Apolipoprotein AI amyloidosis): caused by mutations in the APOAI gene; typically affects kidneys, liver, and peripheral nerves.
• Other hereditary forms involving fibrinogen alpha chain, lysozyme, gelsolin, cystatin C, and other proteins

Senile Systemic Amyloidosis (Wild-type ATTR)

As described in the introduction, this form is caused by age-related destabilization of structurally normal (wild-type) transthyretin. It primarily affects the heart and is considered a disease of aging, predominantly affecting men over 65.

Organ-Specific (Localized) Amyloidoses

These forms affect single organs without systemic involvement:

• Cutaneous amyloidosis: keratin deposits in the skin
• Medullary thyroid carcinoma: calcitonin deposits within the tumor stroma
• Atrial amyloidosis: atrial natriuretic factor deposits in the cardiac atria, increasingly common with age
• Alzheimer’s disease: amyloid-beta (Aβ) deposits in the brain parenchyma and cerebral blood vessels (cerebral amyloid angiopathy)
• Type 2 diabetes: islet amyloid polypeptide (IAPP/amylin) deposits in the pancreatic islets

Risk Factors

The risk factors for developing amyloidosis depend on the specific type, but general predisposing factors include:

• Male sex: approximately 70% of patients with AL amyloidosis are male; ATTRwt almost exclusively affects men
• Age 60–70 years: the peak incidence for most systemic amyloidoses; ATTRwt is most common in men over 65, with prevalence increasing steeply with advancing age
• Pre-existing plasma cell dyscrasias: multiple myeloma, MGUS, and Waldenström macroglobulinemia all predispose to AL amyloidosis
• Chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease, periodic fever syndromes, and chronic infections predispose to AA amyloidosis
• Chronic kidney disease and long-term dialysis: the primary risk factor for DRA
• Family history: essential for identifying hereditary ATTR and other genetic forms, first-degree relatives of patients with hereditary amyloidosis have a 50% risk of carrying the causative mutation
• Ancestry: Val122Ile TTR mutation, associated with predominantly cardiac ATTR, is carried by approximately 3–4% of individuals of West African descent, making hereditary cardiac ATTR amyloidosis significantly more common in this population than previously appreciated

---

Symptoms

The clinical manifestations of amyloidosis are extraordinarily diverse, reflecting the fact that amyloid deposits can accumulate in virtually any organ or tissue. The specific symptoms depend entirely on which organs are involved, to what degree, and which functions are impaired. This organ-system specificity creates a clinical picture that is often initially confusing and non-specific, leading to significant delays in diagnosis, often measured in years.

The most common systemic manifestations, reflecting the frequent and clinically dominant involvement of the heart and kidneys, include:

• Cardiac arrhythmias: atrial fibrillation, heart block, ventricular arrhythmias, reflecting amyloid infiltration of the conduction system and myocardium
• Dyspnea (breathlessness): exertional initially, then at rest, reflecting cardiac dysfunction and/or pleural effusion
• Profound fatigue and exercise intolerance
• Ankle and lower limb edema: reflecting heart failure, nephrotic syndrome (protein loss in urine), or a combination
• Anemia: due to renal failure, bone marrow involvement, or chronic disease
• Fluid retention (general edema): reflecting both cardiac and renal dysfunction
• Proteinuria: loss of proteins (particularly albumin) in the urine, reflecting glomerular damage in renal amyloidosis

Additional symptoms, reflecting involvement of other organ systems, include:

• Skin changes: periorbital purpura (“raccoon eyes”). A highly characteristic but relatively uncommon finding in AL amyloidosis, caused by amyloid deposits in the delicate periorbital capillaries; skin thickening, waxy discoloration
• Cognitive decline and dementia: particularly in amyloidosis affecting the central nervous system
• Early satiety and a sensation of fullness: reflecting amyloid deposits in the stomach and gastrointestinal tract impairing motility and capacity
• Joint pain and stiffness: particularly in DRA (beta-2 microglobulin deposits in joints) and in some forms of hereditary amyloidosis
• Macroglossia (enlarged tongue): a pathognomonic finding in AL amyloidosis, occurring in approximately 10–15% of patients; the tongue becomes enlarged, firm, and may bear indentations from the teeth; can impair speech and swallowing
• Dysphagia (difficulty swallowing)
• Peripheral neuropathy: tingling and numbness in the legs and feet, a burning, painful, or “pins and needles” sensation predominantly in a length-dependent pattern, feet and lower legs affected before hands; caused by amyloid deposits in peripheral sensory nerve fibers
• Hand weakness: particularly bilateral carpal tunnel syndrome, often a presenting feature of ATTRwt that may precede cardiac symptoms by years
• Unexplained significant weight loss

Cardiac Amyloidosis

Cardiac amyloidosis is one of the most clinically important and potentially life-threatening manifestations of systemic amyloidosis. As amyloid fibrils infiltrate the myocardium (heart muscle), the ventricular walls become progressively thickened, stiffened, and granular, changes that are readily apparent on echocardiography and cardiac MRI. This infiltrative cardiomyopathy impairs the heart’s ability to relax and fill during diastole (diastolic dysfunction) and, in advanced cases, also impairs systolic contraction (the heart’s ability to pump blood forward).

The progressive cardiac stiffening creates a clinical picture of restrictive cardiomyopathy, a pattern of heart failure in which the cardiac chambers cannot adequately fill with blood, leading to elevated filling pressures and symptoms of both right- and left-sided heart failure.

Characteristic symptoms of cardiac amyloidosis:

• Arrhythmias: among the earliest and most common manifestations

  • Atrial fibrillation (AF): extremely common in cardiac amyloidosis; the irregular atrial rhythm combined with amyloid infiltration creates a particularly high thromboembolic risk
  • Heart block and conduction abnormalities: amyloid infiltration of the AV node and conduction system impairs normal electrical propagation
  • Ventricular arrhythmias: potentially life-threatening, contributing to sudden cardiac death risk

• Signs and symptoms of heart failure, the dominant clinical syndrome:

  • Ankle, foot, and lower limb edema (dependent edema): fluid accumulation in the tissues due to elevated venous pressure
  • Generalized weakness and fatigue: reflecting reduced cardiac output
  • Progressive dyspnea: initially on exertion, then at rest, and ultimately when lying flat (orthopnea) and in paroxysmal nocturnal episodes
  • Nausea and reduced appetite (hepatic congestion)
  • Ascites (fluid in the abdomen) in advanced right heart failure

• Characteristic clinical features specifically associated with amyloid cardiomyopathy (distinguishing it from other causes of heart failure):

  • Low-voltage ECG despite increased cardiac wall thickness: a paradoxical ECG-echo discordance is a red flag for amyloid infiltration
  • Orthostatic hypotension: from autonomic nerve involvement
  • Poor tolerance of standard heart failure medications: patients with cardiac amyloidosis frequently cannot tolerate beta-blockers, ACE inhibitors, or calcium channel blockers at standard doses

A critical clinical pearl: cardiac amyloidosis, particularly ATTRwt, is dramatically underdiagnosed. Many patients are misidentified as having hypertensive heart disease, “diastolic dysfunction”, or idiopathic heart failure for years before the correct diagnosis is made. Heightened clinical suspicion is essential in older men with unexplained heart failure, particularly if accompanied by prior carpal tunnel syndrome, bilateral carpal tunnel release, or spinal canal stenosis, all of which are increasingly recognized as early manifestations of ATTR amyloidosis preceding overt cardiac involvement.

Renal Amyloidosis

Renal amyloidosis occurs when amyloid fibrils deposit within the delicate filtration units of the kidney (the glomeruli), as well as in the tubules, interstitium, and blood vessels. This disrupts the kidney’s critical function of selectively filtering waste products and toxins from the blood while retaining essential proteins and maintaining fluid and electrolyte balance.

Clinical features of renal amyloidosis:

• Nephrotic syndrome: the hallmark renal presentation, characterized by the triad of:
  • Proteinuria: massive protein loss in the urine (typically >3.5 g/day), the urine appears frothy
  • Hypoalbuminemia: low blood albumin due to urinary losses, impairing the plasma oncotic pressure that keeps fluid within the vasculature
  • Edema: fluid accumulates in the tissues (periorbital edema, puffiness around the eyes, is characteristically worse in the morning; ankle edema worsens throughout the day)
• Signs of progressive renal failure:
  • Rising serum creatinine: reflecting declining glomerular filtration rate (GFR)
  • Oliguria: reduced urine production, reflecting severely compromised kidney filtration
  • Fluid and toxin retention: the kidneys’ inability to excrete metabolic waste products leads to azotemia (elevated blood urea and creatinine) and progressive uremic symptoms
• Renal tubular dysfunction: in addition to glomerular disease, tubular amyloid deposits can impair tubular reabsorption, causing urinary loss of glucose, amino acids, and electrolytes (Fanconi syndrome)

The most common form of amyloidosis causing significant renal disease is AA amyloidosis (in the context of chronic inflammatory disease), followed by AL amyloidosis. ATTR amyloidosis rarely causes significant renal involvement.

Gastrointestinal Amyloidosis

Amyloid deposits throughout the gastrointestinal tract, from the esophagus to the rectum, interfere with normal motility, absorption, digestion, and the mechanical integrity of the gut wall. The specific symptoms depend on the level and extent of GI tract involvement.

Manifestations of gastrointestinal amyloidosis:

• Loss of appetite (anorexia): caused by gastroparesis (delayed gastric emptying), early satiety from reduced gastric compliance, and systemic effects of the disease
• Diarrhea: often secretory in nature, may be severe and debilitating, caused by autonomic neuropathy affecting gut motility, malabsorption, and direct mucosal infiltration
• Nausea and vomiting: particularly if the stomach is significantly affected (gastroparesis)
• Abdominal pain and cramping: related to dysmotility and ischemia from vascular amyloid deposition
• Weight loss: multifactorial, malabsorption, anorexia, increased metabolic demands
• Hepatomegaly (liver enlargement): amyloid deposits in the liver are common in systemic amyloidosis; massive hepatomegaly can develop in AL and AA amyloidosis, sometimes accompanied by mildly elevated liver enzymes and, in severe cases, hepatic synthetic dysfunction (coagulopathy, hypoalbuminemia)
• Gastrointestinal bleeding: amyloid deposits in blood vessel walls impair their structural integrity, predisposing to spontaneous hemorrhage at any level of the GI tract
• Macroglossia: as mentioned above, tongue enlargement is a specific and dramatic manifestation of AL amyloidosis affecting the oropharynx

Amyloid Neuropathy (Neurological Amyloidosis)

When amyloid fibrils deposit in and around peripheral nerves, the spinal cord, and autonomic ganglia, as well as, in some forms, within the brain parenchyma, they produce a range of neurological manifestations, collectively termed amyloid neuropathy or amyloid neurodegenerative disease.

Peripheral sensorimotor neuropathy:

• The classic presentation is a length-dependent ascending sensory neuropathy: sensory symptoms begin in the feet and gradually ascend up the legs, eventually affecting the hands (a “stocking and glove” pattern)
• Symptoms include: tingling and pins-and-needles, burning pain, allodynia (pain from normally non-painful stimuli), and, with progression, loss of sensation (numbness), loss of proprioception (position sense), and loss of vibration sense
• Motor involvement produces progressive distal weakness, predominantly affecting the intrinsic foot and hand muscles

Autonomic neuropathy (often a prominent and disabling feature of hereditary ATTR):

• Orthostatic hypotension and syncope: the most dangerous autonomic manifestation; the blood pressure fails to maintain itself upon standing, leading to lightheadedness, low blood pressure, and fainting, particularly hazardous in elderly patients
• Bladder dysfunction: urinary retention, overflow incontinence, or urgency
• Bowel dysfunction: alternating constipation and diarrhea; fecal incontinence
• Excessive or absent sweating: dysautonomia of sudomotor function
• Erectile dysfunction
• Dry eyes and dry mouth: from autonomic involvement of exocrine glands

Central nervous system involvement:

• Cognitive decline: can occur in some hereditary forms of amyloidosis affecting the CNS
• Stroke: cerebral amyloid angiopathy (CAA), amyloid deposits in cerebral blood vessel walls, increases the risk of both hemorrhagic and ischemic stroke
• Equilibrium and balance problems: reflecting sensory neuropathy and cerebellar involvement

---

Complications

The prognosis of amyloidosis has improved substantially in recent years due to advances in targeted therapy, particularly for AL amyloidosis and ATTR amyloidosis. However, serious and potentially life-threatening complications remain common, particularly when diagnosis is delayed:

Cardiac complications:

• Life-threatening arrhythmias: ventricular fibrillation and ventricular tachycardia can cause sudden cardiac death; atrial fibrillation with rapid ventricular response can precipitate acute hemodynamic deterioration
• Progressive heart failure: ultimately leading to end-stage cardiomyopathy requiring consideration of advanced heart failure therapies
• Congestive heart failure: with severe functional limitation (NYHA class III–IV)
• Thromboembolic events: particularly in the setting of atrial fibrillation, stroke and peripheral embolism carry high morbidity and mortality in this population

Renal complications:

• Nephrotic syndrome: with severe protein loss leading to malnutrition, thromboembolic risk, and infection susceptibility
• End-stage renal disease (ESRD): requiring dialysis or renal transplantation

Neurological complications:

• Severe neuropathic pain: among the most debilitating features of amyloid polyneuropathy
• Progressive sensory loss and fall risk: loss of protective sensation in the feet dramatically increases the risk of injuries, ulceration, and falls; the latter being a leading cause of serious injury and hospitalization in elderly patients with amyloid neuropathy
• Autonomic failure: severe orthostatic hypotension can cause recurrent syncope and falls; neurogenic bladder and bowel dysfunction severely impair quality of life
• Cognitive impairment and dementia: in forms affecting the CNS

---

Diagnosis

An accurate and timely diagnosis of amyloidosis is the essential prerequisite for initiating appropriate targeted therapy. Unfortunately, the diagnosis is frequently delayed by months to years from the onset of symptoms, because the individual manifestations of amyloidosis are non-specific and can easily be attributed to other, more common conditions (heart failure of other causes, diabetic neuropathy, inflammatory bowel disease, etc.). Heightened clinical awareness, particularly in patients with multi-system involvement, is essential for earlier recognition.

The diagnostic workup typically proceeds through several stages:

Clinical History and Physical Examination

A thorough history explores:

• The nature, onset, and progression of symptoms across all organ systems
• Personal and family history of amyloidosis, cardiac disease, neuropathy, renal disease, or other potentially relevant conditions (essential for identifying hereditary forms)
• Prior diagnoses of conditions associated with secondary amyloidosis (rheumatoid arthritis, IBD, chronic infections) or plasma cell dyscrasias (multiple myeloma, MGUS)
• Occupational history, ethnic background (relevant for hereditary ATTR variants)
• Medications, including any immunosuppressants or treatments for inflammatory conditions

Physical examination may reveal characteristic findings such as macroglossia, periorbital purpura, hepatomegaly, peripheral edema, and signs of cardiac failure or neuropathy.

Laboratory Investigations

Blood and urine tests:

• Complete blood count (CBC) and inflammatory markers: assessing for anemia, elevated inflammatory markers (ESR, CRP)
• Renal function panel: serum creatinine, electrolytes, blood urea nitrogen, eGFR
• Urinalysis and 24-hour urine protein quantification: to detect and quantify proteinuria
• Liver function tests: alkaline phosphatase (often elevated in hepatic amyloidosis)
• Serum and urine protein electrophoresis with immunofixation: essential to detect the monoclonal protein (M-protein) that is characteristic of AL amyloidosis; urine immunofixation is more sensitive than serum for detecting light chain excess
• Serum free light chain assay (sFLC): highly sensitive for detecting the abnormal light chain production of AL amyloidosis; the kappa/lambda ratio is a key diagnostic marker and disease monitoring tool
• Cardiac biomarkers: troponin T or I (elevated in cardiac amyloidosis), NT-proBNP (markedly elevated in cardiac amyloidosis and a key prognostic marker in AL amyloidosis staging systems)
• Serum TTR level and stability: in suspected ATTR; genetic testing for TTR mutations is essential for distinguishing wild-type from hereditary ATTR

Biopsy: The Diagnostic Gold Standard

Histological confirmation of amyloid deposits is required for definitive diagnosis. The characteristic finding is the apple-green birefringence under polarized light microscopy when the tissue section is stained with Congo red, a staining technique that binds specifically to the beta-pleated sheet structure of amyloid fibrils. This is pathognomonic of amyloid, regardless of the specific protein type.

The abdominal fat pad biopsy, aspiration of a small sample of subcutaneous fat from the periumbilical (around the navel) region using a fine needle under local anesthesia, is the preferred initial biopsy site in most centers. This minimally invasive procedure is positive in approximately 60–80% of cases of AL amyloidosis and is safe, quick, and easily repeatable. The procedure involves inserting a fine needle into the fatty tissue, aspirating a small tissue fragment, which is then stained and examined under polarized light microscopy.

If abdominal fat pad biopsy is negative but clinical suspicion remains high, additional biopsy sites may be used:

• Bone marrow biopsy: frequently performed in AL amyloidosis workup (also required to assess the underlying plasma cell clone), with a diagnostic yield of approximately 50–60%
• Rectal mucosa biopsy: historically used, still valid; positive in 75–85% of cases
• Minor salivary gland biopsy
• Target organ biopsy (kidney, heart, liver, nerve): provides the highest diagnostic yield but is more invasive and carries higher procedural risk; reserved for cases where less invasive biopsies are non-diagnostic but clinical suspicion remains high

Critical next step after Congo red positivity: identifying the specific amyloid protein type using immunohistochemistry, immunoelectron microscopy, or mass spectrometry-based proteomic analysis of the biopsy sample. This step is essential because the treatment of different amyloidosis types is entirely different, and misidentification leads to inappropriate therapy.

Imaging Studies

For cardiac amyloidosis:

• Echocardiography: the initial cardiac imaging study; classic features include increased ventricular wall thickness, a “sparkling” or “granular” appearance of the myocardium (though this is not specific), diastolic dysfunction, reduced longitudinal strain on speckle-tracking echocardiography (with a characteristic “apical sparing” pattern), and biatrial enlargement
• Cardiac MRI with gadolinium: the most sensitive and specific non-invasive imaging modality for cardiac amyloidosis; characteristic findings include diffuse subendocardial or transmural late gadolinium enhancement and elevated native T1 values on mapping sequences
• Bone scintigraphy with technetium-labeled tracers (DPD, PYP, HMDP): a powerful and highly specific nuclear medicine technique for detecting ATTR cardiac amyloidosis; when grade 2 or 3 cardiac uptake is present without an identifiable monoclonal protein, this is essentially diagnostic of ATTR cardiac amyloidosis, potentially obviating the need for endomyocardial biopsy
• PET/CT: emerging role in amyloidosis imaging, particularly for amyloid-specific tracers (florbetapir, florbetaben, flutemetamol, developed for Alzheimer’s disease but also binding systemic amyloid)

For other organ involvement:

• Abdominal ultrasound: to assess liver size and echogenicity, spleen size, and kidney morphology
• Nerve conduction studies and electromyography (EMG): to characterize peripheral neuropathy
• MRI of spine and peripheral nerves: in suspected neurological involvement

Genetic Testing

Genetic analysis of the TTR gene (and other amyloidogenic genes as indicated by clinical context) is essential when hereditary amyloidosis is suspected. This has critical implications:

• For establishing a precise diagnosis and guiding choice of targeted therapy
• For family screening, identifying at-risk relatives who may benefit from surveillance and early intervention
• For genetic counseling

---

Treatment

The primary therapeutic objective in amyloidosis is to slow or prevent the formation of new amyloid fibrils, and, where possible, to promote the dissolution of already-formed deposits, while managing the functional impairment of affected organs. The treatment landscape of amyloidosis has been transformed over the past decade, moving from largely supportive management to increasingly effective disease-modifying targeted therapies. Treatment strategies vary significantly based on the type of amyloidosis, the specific protein involved, the organs affected, disease severity, and the patient’s overall functional status.

Treatment of ATTR Amyloidosis (Wild-Type and Hereditary)

The understanding and treatment of ATTR amyloidosis represents one of the most exciting recent advances in internal medicine. Two mechanistically distinct classes of disease-modifying drugs are now available:

TTR Stabilizers: Preventing Tetramer Dissociation

These agents work by binding to the TTR tetramer and stabilizing it, preventing the dissociation of the tetramer into monomers and thereby halting the formation of new amyloid fibrils. They do not remove existing amyloid deposits but prevent further accumulation.

• Tafamidis (Vyndaqel, Vyndamax): a potent, orally administered, highly selective TTR stabilizer. The landmark ATTR-ACT trial (2018) demonstrated that tafamidis significantly reduced cardiovascular mortality and cardiovascular-related hospitalizations compared to placebo in patients with ATTR cardiac amyloidosis (both wild-type and hereditary variant). It received FDA and EMA approval and has become the standard of care for ATTR cardiomyopathy. Earlier treatment initiation (before significant cardiac dysfunction develops) appears to provide the greatest benefit.
• Diflunisal: a non-selective NSAID that incidentally stabilizes TTR; used as an alternative where tafamidis is unavailable or not covered; limited by the gastrointestinal and renal side effects common to NSAIDs.

Gene Silencers (RNA-Targeted Therapies): Reducing Hepatic TTR Production

These revolutionary agents target TTR production at the genetic level, reducing the synthesis of the amyloidogenic TTR protein in the liver (where virtually all TTR is produced) and thereby reducing the substrate available for fibril formation.

• Patisiran (Onpattro): an RNA interference (RNAi) therapy that uses lipid nanoparticle-delivered small interfering RNA (siRNA) to silence TTR messenger RNA in hepatocytes, reducing TTR production by approximately 80%. Administered as an intravenous infusion every 3 weeks. Approved for hereditary ATTR polyneuropathy and increasingly studied for cardiac ATTR.
• Inotersen (Tegsedi): an antisense oligonucleotide (ASO) that binds to TTR mRNA and prevents its translation, reducing TTR production. Administered as a weekly subcutaneous injection. Approved for hereditary ATTR polyneuropathy.
• Vutrisiran (Amvuttra): a next-generation RNAi therapy with improved potency and duration of action, requiring only once-quarterly subcutaneous injection. Approved for hereditary ATTR polyneuropathy and more recently also for ATTR cardiomyopathy (based on the HELIOS-B trial results).
• Eplontersen: a next-generation ASO approved for hereditary ATTR polyneuropathy.

Treatment of AL Amyloidosis

The treatment paradigm for AL amyloidosis is fundamentally directed at eradicating or suppressing the abnormal plasma cell clone in the bone marrow that produces the amyloidogenic light chains. The depth of hematological response (how completely the monoclonal protein production is eliminated) is directly linked to the degree of organ improvement and survival.

High-dose chemotherapy and autologous stem cell transplantation (ASCT)

For eligible patients (those with good performance status and without severe cardiac or multi-organ involvement, approximately 20–25% of newly diagnosed patients), high-dose melphalan followed by ASCT remains the most effective method of achieving deep and durable hematological responses. Complete hematological response (undetectable M-protein) is associated with substantial organ improvement and long-term survival.

Modern combination regimens

For the majority of patients who are not eligible for ASCT, current standard-of-care treatment combines agents from multiple drug classes:

• Proteasome inhibitors: bortezomib (Velcade), carfilzomib, cornerstone drugs that inhibit the proteasome pathway essential for plasma cell survival
• Immunomodulatory agents (IMiDs): lenalidomide (Revlimid), pomalidomide, modulate the immune environment and have direct anti-plasma cell effects
• Anti-CD38 monoclonal antibodies: daratumumab (Darzalex), a monoclonal antibody that has dramatically improved response rates and outcomes in AL amyloidosis when combined with standard regimens (CyBorD + daratumumab is now a leading frontline option). Daratumumab binds CD38 on plasma cells, triggering their destruction through multiple immune mechanisms.

The addition of daratumumab to established regimens has produced very high rates of deep hematological response (very good partial response or better in >80% of patients), marking a major advance in AL amyloidosis treatment.

Treatment of AA Amyloidosis

The modern therapeutic approach to AA amyloidosis focuses on treating the underlying inflammatory disease that is driving the chronic overproduction of serum amyloid A protein. Effective control of the primary inflammatory condition is the most important factor in preventing further amyloid deposition and stabilizing or improving organ function.

Targeted biological therapies have largely replaced non-specific anti-inflammatory treatment:

• Anti-TNF-alpha agents (e.g., adalimumab, etanercept), for rheumatoid arthritis and other TNF-driven inflammatory diseases
• Anti-interleukin-1 agents (e.g., anakinra, canakinumab), particularly effective for periodic fever syndromes (FMF, CAPS, TRAPS). These conditions were among the first to demonstrate dramatic benefit from IL-1 blockade
• Anti-interleukin-6 agents (e.g., tocilizumab), for inflammatory arthritis and related conditions

Specific agents for AA amyloidosis:

• Eprodisate (and its successor KIACTA), these agents compete with glycosaminoglycans for binding to amyloid fibrils, potentially inhibiting fibril elongation and promoting fibril dissolution, though clinical trial results have been mixed.
• Colchicine, remains the treatment of choice for FMF and effectively prevents AA amyloidosis in FMF patients when used long-term.

Organ Transplantation

Organ transplantation plays an important role in selected patients:

• Liver transplantation: indicated in certain variants of hereditary ATTR amyloidosis where the primary site of TTR production is the liver. By replacing the liver, the source of mutant TTR, liver transplantation eliminates production of the amyloidogenic protein, though it does not remove pre-existing amyloid deposits and may not benefit patients with advanced cardiac or neurological involvement. The advent of pharmacological TTR silencers has somewhat reduced the role of liver transplantation.

• Kidney transplantation: considered for patients with ESRD from AA or AL amyloidosis, after effective treatment of the underlying condition (to prevent rapid recurrence in the transplanted kidney). It is a treatment for the end-stage renal manifestation, not for the underlying amyloidosis.

• Heart transplantation: occasionally considered in highly selected patients with severe cardiac amyloidosis, particularly in ATTRv patients who can simultaneously receive or have previously received liver transplantation.

Supportive and Organ-Specific Management

Targeted amyloid therapy is always complemented by comprehensive supportive management of affected organs, coordinated across a multidisciplinary specialist team (cardiologist, nephrologist, neurologist, gastroenterologist, pain specialist, dietitian, physiotherapist, and psychologist):

Cardiac support:

• Diuretics: reduce fluid congestion in heart failure but must be used carefully (cardiac amyloid patients are particularly sensitive to volume depletion)
• Anticoagulation: essential in patients with atrial fibrillation (very high thromboembolic risk in cardiac amyloidosis)
• Rate control: standard rate control agents (beta-blockers, calcium channel blockers) may be poorly tolerated in cardiac amyloidosis (they can worsen hemodynamic compromise); digoxin should be avoided (binds amyloid fibrils and can cause toxicity)
• ICD (Implantable Cardioverter-Defibrillator) and pacemaker: in patients with life-threatening arrhythmias or high-degree heart block
• Cardiac resynchronization therapy (CRT) in eligible patients with conduction abnormalities

Renal support:

• Careful blood pressure management
• Dietary protein and sodium optimization
• Renin-angiotensin system blockade (ACE inhibitors/ARBs) for proteinuria reduction (used with caution in the setting of significant cardiac involvement)
• Renal replacement therapy (dialysis) for ESRD

Neurological support:

• Neuropathic pain management: gabapentin, pregabalin, duloxetine, pharmacological management of painful neuropathy
• Fall prevention programs: essential in patients with sensory neuropathy and postural instability
• Orthostatic hypotension management: graduated compression stockings, head-of-bed elevation, fludrocortisone, midodrine, droxidopa
• Bladder management: timed voiding, intermittent self-catheterization, medications as appropriate

Nutritional support:

• Dietitian input for malabsorption, weight loss, and dietary optimization
• Enteral or parenteral nutrition in severe gastrointestinal involvement

Physical rehabilitation:

• Physiotherapy programs to maintain mobility, strength, and balance
• Occupational therapy for adaptive strategies in daily living

Psychological support:

• Recognition and treatment of anxiety, depression, and adjustment difficulties, common in patients with a serious, progressive chronic disease
• Patient education and support group connections (e.g., through national amyloidosis foundations)

Potential for Organ Recovery

An important and often underappreciated aspect of amyloidosis management is that functional organ recovery is possible when treatment achieves a deep and early reduction in the amyloidogenic protein supply. Amyloid deposits can regress over months to years when the protein substrate is eliminated, and organ function, particularly renal function, can partially or substantially recover. The likelihood and degree of recovery depend on the type of amyloidosis, the organ involved, the reversibility of structural damage at the time of diagnosis, and the depth of treatment response. This provides a powerful argument for early diagnosis and aggressive treatment initiation before irreversible structural damage is established.

---

Sources and Bibliography

• Merlini G, Bellotti V. (2003). Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349(6):583–596.
• Maurer MS, et al. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-ACT trial). New England Journal of Medicine, 379(11):1007–1016.
• Adams D, et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis (APOLLO trial). New England Journal of Medicine, 379(1):11–21.
• Kastritis E, et al. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis (ANDROMEDA trial). New England Journal of Medicine, 385(1):46–58.
• Wechalekar AD, Gillmore JD, Hawkins PN. (2016). Systemic amyloidosis. The Lancet, 387(10038):2641–2654.
• Gillmore JD, Maurer MS, Falk RH, et al. (2016). Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 133(24):2404–2412.
• Falk RH, Alexander KM, Liao R, Dorbala S. (2016). AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology, 68(12):1323–1341.
• European Heart Journal - 2023 ESC Guidelines for the diagnosis and treatment of cardiac amyloidoses.